I'm new to this board, and have not dabbled in BioTechs much, but I've seen what can be gained from a successful run.
Part of the reason I'm here is that I've sorta stumbled over a possible runner, and all things I've seen point to it being successful, but would like to see what you all think.
The Ticker is: PROT Proteonomix, Inc SS is: 6,735,556 O/S 4,431,155 Float, verified by me direct from the T/A 2 days ago.
Here is a recap from an Investors Info sheet from the company.
Proteonomix is a public biotechnology corporation. We have developed a range of stem cell related technologies in cooperation with John’s Hopkins University and the University of Miami.
We are immediately ready to enter phased human trials on two medical treatments and to launch a line of anti-aging cosmeceuticals based upon these technologies.
Proteoderm: A line of Anti-Aging products based upon a matrix of proteins secreted from our stem cell growth platform that stimulates collagen formation.
UMK 125: A treatment for liver disease and other possible applications using a combination of two approved drugs to mobilize particular bone marrow stem cells.
StromaCel: A treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bon marrow and administered via IV solution.
The company is now seeking funding. Initial use of funding will be to perform human trials for UMK 125, scheduled for start in Q3 2011 with U Miami and to launch Proteoderm through a physician network. We further intend to begin treating patients with StromaCel in medical tourism destinations, such as the Dominican Republic where we have several facilities under contract.
Their last several press releases indicate that they are ready to begin testing their UMK 125 Liver treatment. Apparently there is some affiliation with the University of Miami Med Center?
It appears that they hold many patents and have several subsidiary companies as well. These companies seem to be set up to cover various parts of the research, manufacture and distribution of their therapies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.